SEI Investments’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-622
| Closed | -$112K | – | 3650 |
|
|
2017
Q3 | $112K | Sell |
622
-5,107
| -89% | -$712K | ﹤0.01% | 2047 |
|
|
2017
Q2 | $594K | Buy |
5,729
+5,450
| +1,953% | +$445K | ﹤0.01% | 1578 |
|
|
2017
Q1 | $22K | Sell |
279
-3,458
| -93% | -$214K | ﹤0.01% | 2320 |
|
|
2016
Q4 | $167K | Sell |
3,737
-2,258
| -38% | -$111K | ﹤0.01% | 1832 |
|
|
2016
Q3 | $334K | Buy |
5,995
+1,385
| +30% | +$77.2K | ﹤0.01% | 1552 |
|
|
2016
Q2 | $230K | Sell |
4,610
-3,090
| -40% | -$152K | ﹤0.01% | 1518 |
|
|
2016
Q1 | $353K | Buy |
7,700
+3,424
| +80% | +$166K | ﹤0.01% | 1386 |
|
|
2015
Q4 | $264K | Sell |
4,276
-25,712
| -86% | -$1.81M | ﹤0.01% | 1491 |
|
|
2015
Q3 | $1.67M | Buy |
29,988
+16,446
| +121% | +$1.03M | 0.02% | 867 |
|
|
2015
Q2 | $826K | Buy |
13,542
+3,542
| +35% | +$202K | 0.01% | 1035 |
|
|
2015
Q1 | $576K | Buy |
10,000
+6,144
| +159% | +$412K | 0.01% | 1135 |
|
|
2014
Q4 | $222K | Buy |
+3,856
| New | +$162K | ﹤0.01% | 1376 |
|
SEI Investments's KITE Position: Q4 2017 in Review
SEI Investments sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 622 shares — an estimated $112K sold.
SEI Investments first reported a position in KITE in Q4 2014 and held it in 12 quarters. The position peaked at $1.67M in Q3 2015. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- SEI Investments reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- SEI Investments sold 622 Kite Pharma, Inc. shares in Q4 2017, an estimated $112K.
- SEI Investments first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 12 quarters.
- SEI Investments's Kite Pharma, Inc. position peaked at $1.67M in Q3 2015.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on SEI Investments's 13F filing for Q4 2017, filed 8 Feb 2018.